Alternative CRISPR Genome Editing Method Developed

Merck has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies.

This new technique, called ‘proxy-CRISPR’, provides access to previously unreachable areas of the genome. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering. However, proxy-CRISPR provides a rapid and simple method to increase their usability without the laborious need to re-engineer native CRISPR proteins.

The company has filed several patent applications on the proxy-CRISPR technology. These patent applications directed to the proxy-CRISPR technology are just some of several CRISPR patent application filings made by the company since 2012.

"With more flexible and easy-to-use genome editing technologies, there is greater potential in research, bioprocessing and novel treatment modalities," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "As a leader in genome editing, Merck's new technology is just one example of our commitment to solving challenges in the genome editing field, and we will continue to make CRISPR research a priority."

Merck's research on proxy-CRISPR, ‘Targeted Activation of Diverse CRISPR-Cas Systems for Mammalian Genome Editing via Proximal CRISPR Targeting’, was published in the April 7, 2017 edition of Nature Communications. The article explains how to make CRISPR more efficient, flexible and specific by opening up the genome for the cutting of DNA, giving researchers more editing options.

The new technology is a follow-on to Merck's existing CRISPR applications. The company's next suite of genome editing tools for the research community, to be launched later in 2017, will include novel and modified versions of Cas and Cas-like proteins.